PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Conditions: Esophageal Neoplasms Interventions: Radiation: Radiation; Drug: TP or PF regimen depended on investigator ' s choice.; Biological: PD-1 inhibitor Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University Cancer Hospital& Institute; Beijing Cancer Prevention& Treatment Society; Hebei Medical University Fourth Hospital; Tianjin Medical University Cancer Institute and Hospital; Fujian Cancer Hospital; Anyang Tumor Hospital; The First Affiliated Hospital with Nanjing Medical University; Sichuan Cancer Hospital and Research Institute; Tengzhou Central People ' s Hospital; The Fi...
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Conditions: Esophageal Neoplasm Metastatic; Esophageal Cancer Stage IVb Interventions: Drug: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator ' s choice.; Biological: PD-1 inhibitor; Radiation: Consolidation Radiation; Radiation: Salvage Radiation Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University Cancer Hospital& Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Conditions: Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma Interventions: Drug: ABBV-400 Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
Conditions: Hypoxia; Gastric Polyp; Colon Cancer; Esophageal Cancer Interventions: Device: the COMBO Endoscopy Oropharyngeal Airway; Device: Regular Nasal Cannula Sponsors: RenJi Hospital; Tianjin Medical University General Hospital; The First Affiliated Hospital with Nanjing Medical University; First Affiliated Hospital Xi ' an Jiaotong University; Qianfoshan Hospital; Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
Conditions: Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Endoscopic Ultrasound; Procedure: Esophagogastroduodenoscopy; Drug: Fluorouracil; Radiation: Hypofractionated Radiation Therapy; Drug: Leucovorin Calcium; Drug: Ox...
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)
Conditions: Esophageal Squamous Cell Carcinoma (ESCC); PD-1 Inhibitors Interventions: Drug: IBI110+Sintilimab Sponsors: The First Affiliated Hospital of Zhengzhou University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections
Conditions: Esophageal Neoplasms; Endoscopic Mucosal Resection; Hyaluronic Acid Interventions: Procedure: Submucous Endoscopic Dissection with hydroxyethylamide; Procedure: Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye) Sponsors: Instituto do Cancer do Estado de S ão Paulo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
Conditions: Barrett Esophagus; Barretts Esophagus With Dysplasia; Barrett ' s Esophagus Without Dysplasia; Esophageal Adenocarcinoma Interventions: Device: Cytosponge Procedure; Diagnostic Test: Endoscopic Assessment Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.
Conditions: Esophageal Neoplasms; Dysphagia Interventions: Device: Fully Covered Esophageal Prosthesis (FC-SEMS); Device: Partially Covered Esophageal Prosthesis (PC-SEMS) Sponsors: Instituto do Cancer do Estado de S ão Paulo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
G-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-through
Conditions: Gastroparesis; Esophageal Cancer Sponsors: Institute for Clinical and Experimental Medicine; Jackson Memorial Hospital and the Lennar Foundation Medical Center; Universit äres Speiseröhrezentrum Hamburg; University Hospital, Martin; The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Regional Institute of Gastroenterology, Cluj-Napoca; Universitätsklinikum Augsburg; Universitätsspital Zürich; Universitaire Ziekenhuizen KU Leuven; King Ed ward VII ' s Hospital/King ' s College Hospital; John Hopkins Hospital; Columbia University Irving Medical Centre; A. Gemelli IRCCS Polyclinic Fou...
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
Conditions: Atrial Fibrillation; Esophageal Carcinoma Interventions: Drug: Amiodarone Hydrochloride; Other: Saline Sponsors: OHSU Knight Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: 1% Lugol ' s iodine solution; Drug: 5% Lugol ' s iodine solution Sponsors: Xijing Hospital of Digestive Diseases; Ankang Central Hospital; The First Affiliated Hospital of ShiheziI University; Xi ' an International Medical Center Hospital; Air Force 986 Hospital; Xianyang Central Hospital (the second people ' s Hospital of Xianyang City) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Endoscopic Submucosal Dissection Versus Esophagectomy for Early Esophageal Carcinoma
Conditions: Esophageal Cancer Interventions: Procedure: Endoscopic submucosal dissection; Procedure: Esophagectomy Sponsors: Changhai Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy
Conditions: Esophageal Cancer Interventions: Other: follow up Sponsors: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Tirellizumab Plus Concurrent Chemoradiation in Older With ESCC
Conditions: Esophageal Cancer Interventions: Drug: Arm A; Drug: Arm A; Radiation: Arm A; Drug: Arm B; Radiation: Arm B Sponsors: Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital and Research Institute; Shanxi Province Cancer Hospital; Henan Cancer Hospital; Hunan Cancer Hospital; The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
